Back to Search
Start Over
Messenger RNA vaccines against SARS-CoV-2
- Source :
- Cell
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3-4 weeks apart. To view this Bench to Bedside, open or download the PDF.
- Subjects :
- 2019-20 coronavirus outbreak
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19)
T-Lymphocytes
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Treatment outcome
Antigen-Presenting Cells
Biology
Placebo
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
Drug Delivery Systems
0302 clinical medicine
Humans
030304 developmental biology
B-Lymphocytes
Vaccines, Synthetic
0303 health sciences
Messenger RNA
SARS-CoV-2
COVID-19
Bench to Bedside
Virology
Bench to bedside
Treatment Outcome
Liposomes
Spike Glycoprotein, Coronavirus
Nanoparticles
Synthetic immunology
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 00928674
- Database :
- OpenAIRE
- Journal :
- Cell
- Accession number :
- edsair.doi.dedup.....4d9fdb5ba07920ad7ad056de92a50574
- Full Text :
- https://doi.org/10.1016/j.cell.2020.12.039